Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04819685
Other study ID # KFP for RTI rectal injury
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2021
Est. completion date March 1, 2025

Study information

Verified date March 2021
Source Peking Union Medical College Hospital
Contact Fuquan Zhang, MD
Phone +86 010 6915 5485
Email zhangfuquan3@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A total of 520 cases will be randomly divided into Kang Fu Pen (liquid dressing) enema intervention group (experimental group) and non-enema intervention group (control group), according to the ratio of 1:1.


Description:

All patients are planned to receive radical concurrent chemoradiotherapy. Intensity modulated radiotherapy (IMRT) will be used for external irradiation, with a dose of 45-50.4Gy /25-28 fractions. Combined three-dimensional intracavitary/interstitial (IC/IS) brachytherapy was applied. The preferred dose fraction plan is 6Gy*5 fractions, or 7Gy*4 fractions. Whether to adopt supplement radiotherapy can be decided by the tumor regression. Cisplatin 40 mg/m2 is recommended as the first choice for concurrent chemotherapy, and TP or TC can also be considered. Single-drug weekly therapy should be completed for at least 3 cycles, and combined 3-week regimen should be completed for at least 1 cycle. Experimental group: from three days before radiotherapy to one week after radiotherapy, Kang Fu Pen (recombinant human superoxide dismutase) retention enema, 50ml/ time, once every other day. When rectal mucosa II degree reactions (NCI-CTCAE 5.0) occur, it is changed to 1 day/time until 1 week after mucosal remission. Control group: 3 days before radiotherapy to the end of radiotherapy, no drug retention enema was used.


Recruitment information / eligibility

Status Recruiting
Enrollment 520
Est. completion date March 1, 2025
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. The patient is completely voluntary and has the ability to sign the research informed consent form within 30 days before enrollment; 2. Age =18 years old and =65 years old; 3. Pathologically confirmed cervical cancer; 4. Those with IB3, IIA2, IIB, IIIA, IIIB, and those with cervical tumor = 4cm or involved parametrial in IIIC1 and IIIC2 (FIGO 2018 staging); 5. ECOG score 0-2 points; 6. The complete blood count and basal metabolic indexes in the 14 days before enrollment must meet the following requirements: NEUT=1.5*10^9/L, HGB=80g/L, PLT=100*10^9/L, blood creatinine < 1.5mg/dl (133umol/L), AST and ALT are within 2 times of the upper limit of normal; 7. Those who have had regular bowel movements and had a negative stool routine test + occult blood before enrollment. Exclusion Criteria: 1. Those who have a history of allergy to superoxide dismutase use; 2. Patients with skin and mucous membrane infections, patients with obvious empyema or pelvic inflammatory disease; 3. Those who have had chronic colitis, ulcerative colitis, and non-specific proctitis in the past; 4. Those who have received cervical cancer surgery (including pelvic or retroperitoneal lymphadenectomy, excluding tumor biopsy), radiotherapy or chemotherapy; 5. Those who are expected to be unable to receive brachytherapy, or brachytherapy needs to use tumor elimination, uterine tube inserted alone in one fraction, or template plan; 6. Those who need to use fluorouracil or capecitabine or tigio in the concurrent chemotherapy regimen; 7. History of other malignant tumors; 8. Pregnant or lactating women; 9. Accompanied by active infection and fever; 10. Other serious diseases that may significantly affect the compliance of clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment.

Study Design


Intervention

Drug:
KANG FU PEN
FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing

Sponsors (16)

Lead Sponsor Collaborator
Peking Union Medical College Hospital Beijing Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chinese PLA General Hospital, Fudan University, Guizhou Cancer Hospital (The Affiliated Cancer Hospital of Guizhou Medical University), Henan Cancer Hospital, Jiangsu Cancer Institute & Hospital, Jilin Provincial Tumor Hospital, Peking University Third Hospital, Shandong Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Sun Yat-sen University, Xiangya Hospital of Central South University, Xijing Hospital Attached Air Force Medical University, Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of rectal mucosal injury caused by acute radiation the incidence of Vienna rectoscopy score =2 within 1 week after radiotherapy. Vienna rectoscopy score was used. Within 1 week after radiotherapy
Secondary Degree of rectal injury caused by chronic radiation incidence of RTOG score =2 at 3 to 24 months after radiotherapy. If the RTOG score =2 at 3 to 24 months after radiotherapy, rectoscopy will be used to evaluate the degree. If the RTOG score is 0 or 1, clinical classification is enough. 3 to 24 months after radiotherapy
Secondary Quality of life score EORTC QLQ-C30 (V3.0) was used to score quality of life before, during, and after radiotherapy. 3 to 24 months after radiotherapy
Secondary overall survival (OS) Overall survival (OS) is defined as the time interval from randomization to death from any cause or, if no death, to the last follow-up. 3 years after radiotherapy
Secondary disease-progression-free survival (PFS) Progression-free survival (PFS) is defined as the time between randomization and the occurrence of local or regional recurrence, or distant metastasis, or death from any cause, based on the time of the first event and, if none of these events occurred, to the last follow-up. 3 years after radiotherapy
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A